Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of injected omalizumab in seasonal allergic rhinitis
ChiCTR2500098369Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of omalizumab in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Rhinoconjunctivitis symptom score. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ChiCTR2500098369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098369.